Procognia (Israel) Ltd. and Seahorse Bioscience successfully completed the first stage in a combine study demonstrating the synergistic effect of their technologies to expand and significantly improve biopharmaceutical drugs development while reducing dramatically development cost, risks and time to market - 25/04/2010





Procognia has received Helsinki Committee authorization from the Tel HaShomer Medical Center to carry out a diagnostic trial focusing on colon cancer - 21/01/2010





Developing Antibodies for the Diagnosis and Treatment of Cancer - 03/12/2009





Collaboration between GP Bioscience and Procognia in the Glycodiagnostics Field - 15/09/2009





New patent application - Diagnosis of cancers through glycome analysis - 08/09/2009





Procognia: NIS 1.9 million European grant for the early detection and monitoring of prostate cancer - 16/06/2009





License agreement with GP BioScience: - 10/06/2009

Procognia has contracted in a license agreement and collaboration with GP BioScience



Presentation to the FDA:  - 24/11/2008

The GlycoScope HTS glycoanalysis platform technology was presented to the FDA



Presentation to the EMEA:  - 30/10/2008

The GlycoScope HTS glycoanalysis platform technology was presented on 30/10/2008 to the BMWP



Presentation in the 4th Glycan forum in Berlin: - 23/05/2008

Presentation title:"Development of a glycosylated biosimilar product: Case study"



Presentation in Glycobiology and Medicine Symposium in Dublin:  - 21/10/2007

Presentation title: "GLYCOANALYSIS OF CELL MEMBRANE PROTEINS ON A LECTIN ARRAY"